Metamark Genetics, Inc is determined to transform outcomes and improve survival for cancer patients by empowering personalized treatment decisions. Metamark is developing prognostic diagnostic tests, using its proprietary Prognosis Determinants™. These tests will contribute to optimized treatment of early stage cancer through knowledge of the tumor’s molecular characteristics and risk profile.
Our goal is to fundamentally change the way in which cancer is diagnosed and treated with the prospect of better survival and reduced morbidity for patients and significant cost savings for health care systems.
Metamark Genetics Board of Directors Appoints Shawn M. Marcell President
and Chief Executive Officer
read more >
Metamark Genetics Completes
$13 Million Series B Financing;
Announces Leadership Changes . . .
read more >
Metamark science featured in the
New York Times
Metamark Genetics Completes
Proof-of-Concept for
Protein-based Prostate Cancer . . .
read more >
Quantitative multi-parameter assays that define risk of metastasis and recurrence by measuring the functional genetic elements that drive tumor aggressiveness. click here >
Peter Blume-Jensen from Metamark Genetics
Peter Blume-Jensen, Chief Scientific Officer of Metamark Genetics, sits down with Slone Partners at the Personalized Medicine Conference in Boston to discuss their novel platform Prognosis.
Peter Blume-Jensen of Metamark Genetics
on Prognosis Determinants
Through its proprietary Prognosis Determinant™ Discovery Platform, Metamark has identified and validated functionally active genetic determinants of metastasis that are critical to the progression of a broad spectrum of tumor types. watch >
Metamark is building a world-class scientific team with the passion and determination to transform cancer care. To view our list of openings on our Careers page, click here >
